Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health Services Inc. has demonstrated strong performance, particularly in its OP Rehab segment, which has grown in the double-digit percentage range while maintaining attractive margins. The Pharmacy Solutions segment has seen significant revenue growth, with specialty revenue for 2025 reaching approximately $2.6 billion, reflecting a year-over-year increase of 43%, and an increase in EBITDA margins, indicating further potential for profitability. Additionally, the Provider Services division benefits from stable reimbursement rates and strategic acquisitions that enhance growth prospects, complemented by expected increases in specialty drug spending and cost-saving efficiencies from its services.

Bears say

The financial outlook for BrightSpring Health Services Inc. appears negative due to a concerning reliance on client budgets, which, if weakened, could significantly impact the company's revenue and overall business stability. Additionally, potential reductions in prescription writing by healthcare professionals may diminish revenues, operating results, and cash flow, posing further risks to financial performance. Furthermore, the company's substantial debt load may constrain its ability to invest in growth opportunities, exacerbating challenges in a competitive healthcare environment.

BTSG has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 9 analysts, BTSG has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.